News

Geistlich Pharma’s collagen membrane authorized for use in the USA

The Geistlich Nexo-Gide has obtained clearance from the US Food and Drug Administration (FDA). The collagen membrane developed by Geistlich Pharma supports the healing process for tendon and ligament injuries.

Geistlich Pharma's collagen membrane supports the healing process in tendon and ligament injuries.
Geistlich Pharma's collagen membrane supports the healing process in tendon and ligament injuries. Generic Image: kinkate/Pixabay

The Geistlich Nexo-Gide supports the body’s own healing process for tendon and ligament injuries, Geistlich Pharma writes in a press release. The absorbable, bi-layered collagen membrane developed by the Lucerne-based subsidiary of the Geistlich Group from Schlieren in the canton of Zurich increases the likelihood of successful surgical procedures for patients suffering from severe tendon and ligament injuries.

“Tendon injuries are still a major clinical challenge”, comments Carrie Hartill, Business Unit Director at Geistlich Surgery, in the press release. She explains that tendon and ligament injuries account for nearly half of all the 32 million musculoskeletal injuries recorded in the USA each year. The Geistlich Nexo-Gide is particularly well-suited for use in scenarios where there is no significant loss of tendon tissue.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Share
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program